title: Influence of 99mTc-tetrofosmin SPECT myocardial perfusion imaging on the prediction of future adverse cardiac events.
abstract: BACKGROUND
  The impact of myocardial perfusion imaging (MPI) on prediction of risk for future cardiac events was examined by comparing predictions based on clinical information alone and in combination with MPI findings.
  
  
  RESULTS
  A 3-cardiologist Cardiac Event Prediction Panel (CEPP) estimated three-year cardiac event (non-fatal MI; aborted sudden cardiac death; cardiac death) risk based on clinical data (C) for 371 subjects. CEPP repeated this estimation after receiving Summed Stress Scores (SSS) and Summed Rest Scores (SRS) from blinded reading of rest-stress (99m)Tc-tetrofosmin MPI SPECT studies (C + MPI). The C and C + MPI estimates were then compared with three-year and total event rates. MPI was normal (SSS </= 3) in 227 patients (61%), mildly abnormal (SSS 4-8) in 31 (8%), moderately abnormal (SSS 9-13) in 36 (10%), and severely abnormal (SSS > 13) in 77 (21%). Eighteen cardiac events occurred within 3 years and 33 occurred during a mean follow-up of 3.9 years. C + MPI estimates of low risk (<1-1.5%/year) identified significantly more patients who did not have events than C. C + MPI three-year event-rate predictions were more accurate than those made with C (P < .01). C + MPI categorization also provided better delineation of incremental risk on time-to-event analyses.
  
  
  CONCLUSIONS
  (99m)Tc-tetrofosmin MPI single photon emission computed tomography (SPECT) findings significantly improve accuracy of cardiac event rate prediction compared to those based on clinical information alone.
authors.affiliation: Drexel University College of Medicine, Philadelphia, PA, USA.
authors.forename: Diwakar
authors.initials: D
authors.lastname: Jain
authors.forename: Harry
authors.initials: H
authors.lastname: Lessig
authors.forename: Riti
authors.initials: R
authors.lastname: Patel
authors.forename: Leonard
authors.initials: L
authors.lastname: Sandler
authors.forename: Fred
authors.initials: F
authors.lastname: Weiland
authors.forename: Steven L
authors.initials: SL
authors.lastname: Edell
authors.forename: M
authors.initials: M
authors.lastname: Elizabeth Oates
authors.forename: Erin
authors.initials: E
authors.lastname: O'Malley-Tysko
authors.forename: Natalie
authors.initials: N
authors.lastname: Khutoryansky
authors.forename: Arnold F
authors.initials: AF
authors.lastname: Jacobson
mesh_terms: D000368:Aged; D002309:Cardiology / Q000379:methods; D005080:Exercise Test; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D055414:Myocardial Perfusion Imaging / Q000009:adverse effects* / Q000379:methods*; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D011379:Prognosis; D019275:Radiopharmaceuticals; D012306:Risk; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D016896:Treatment Outcome
chemical_list: D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C078700:technetium tc-99m tetrofosmin